Valeo Financial Advisors LLC boosted its stake in Glaukos Corp (NYSE:GKOS) by 9.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,432 shares of the medical instruments supplier’s stock after acquiring an additional 202 shares during the period. Valeo Financial Advisors LLC’s holdings in Glaukos were worth $132,000 as of its most recent SEC filing.
A number of other hedge funds also recently modified their holdings of GKOS. Harvest Fund Management Co. Ltd acquired a new stake in shares of Glaukos in the 2nd quarter worth $39,000. Marshall Wace North America L.P. acquired a new position in shares of Glaukos during the first quarter worth about $55,000. Exchange Traded Concepts LLC acquired a new position in shares of Glaukos during the fourth quarter worth about $86,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Glaukos by 24.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,825 shares of the medical instruments supplier’s stock worth $154,000 after acquiring an additional 551 shares during the period. Finally, Evoke Wealth LLC purchased a new position in Glaukos during the third quarter worth about $174,000.
Shares of Glaukos stock opened at $57.65 on Monday. The company has a 50-day moving average of $56.74 and a two-hundred day moving average of $64.18. Glaukos Corp has a 12-month low of $53.19 and a 12-month high of $84.65. The company has a current ratio of 6.32, a quick ratio of 5.94 and a debt-to-equity ratio of 0.42. The stock has a market cap of $2.10 billion, a PE ratio of -106.76 and a beta of 1.59.
Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.10) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.07. Glaukos had a negative return on equity of 4.01% and a negative net margin of 8.60%. The business had revenue of $58.51 million for the quarter, compared to analyst estimates of $56.96 million. During the same quarter in the previous year, the company earned ($0.17) EPS. The company’s quarterly revenue was up 33.2% on a year-over-year basis. On average, sell-side analysts forecast that Glaukos Corp will post -0.41 EPS for the current fiscal year.
A number of equities research analysts have weighed in on GKOS shares. BTIG Research reaffirmed a “hold” rating on shares of Glaukos in a report on Wednesday, October 30th. JPMorgan Chase & Co. cut their target price on Glaukos from $90.00 to $65.00 and set an “overweight” rating for the company in a research note on Friday, December 20th. Bank of America cut Glaukos from a “buy” rating to an “underperform” rating and set a $67.00 price target for the company. in a report on Monday, September 30th. Wells Fargo & Co downgraded Glaukos from an “overweight” rating to an “underweight” rating and set a $58.00 price target on the stock. in a research note on Thursday, December 12th. Finally, Berenberg Bank upgraded Glaukos from a “hold” rating to a “buy” rating and lifted their price target for the company from $60.00 to $65.00 in a research note on Monday, January 6th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $69.60.
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery.
Featured Story: 52-Week Highs and Lows
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.